Pietro Bortoletto
Reproductive Endocrinology Boston, MA Medical Doctor
NPI 1720477516 CMS profile 8800240
75 Francis St, Asb1-3-608A, Boston, MA 02115
General payments
$37,708
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$127,075
Through program year 2025, Pietro Bortoletto of Boston, MA is reported in the CMS Open Payments database as having received $37,708 across 39 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $127,075 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,455 | 12 | |
| 2024 | General | $14,740 | 19 | |
| 2023 | General | $133 | 2 | |
| 2022 | General | $1,278 | 2 | |
| 2021 | General | $50 | 2 | |
| 2020 | General | $51 | 2 |
Beside peers
- Pietro Bortoletto
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Pietro Bortoletto were reported at $21,455. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Pietro Bortoletto | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $77–$425 | $163 |
| 2020 | $51 | $81 | $35–$182 | $114 |
| 2021 | $50 | $102 | $43–$247 | $132 |
| 2022 | $1,278 | $139 | $62–$303 | $149 |
| 2023 | $133 | $141 | $65–$285 | $160 |
| 2024 | $14,740 | $144 | $65–$302 | $164 |
| 2025 | $21,455 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
39 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Massachusetts
Antonio Gargiulo
Reproductive Endocrinology · Boston, MA
Kim Thornton
Reproductive Endocrinology · Waltham, MA
Samuel Pauli
Reproductive Endocrinology · Lexington, MA
Rita Sneeringer
Reproductive Endocrinology · Waltham, MA
Alan Penzias
Reproductive Endocrinology · Waltham, MA
Aaron Styer
Reproductive Endocrinology · Chestnut Hill, MA
Related records
Reproductive Endocrinology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.